Gene activity altered in certain brain cells of people with C9-ALS
The genetic activity of certain brain cells, namely excitatory neurons and astrocytes, is altered in people with amyotrophic lateral…
Articles by Marisa Wexler, MS
Zydus launches Phase 2 trial of anti-inflammatory ZYIL1
Zydus Lifesciences has launched a Phase 2 clinical trial to evaluate the safety and effectiveness of its experimental anti-inflammatory…
TUDCA at higher daily dose seen to extend survival: ALS registry study
People with amyotrophic lateral sclerosis (ALS) who are treated daily with 1,000 mg or higher doses of tauroursodeoxycholic…
FDA advisory committee votes against NurOwn approval for ALS
In a nearly unanimous vote, an advisory committee to the U.S. Food and Drug Administration (FDA) said there’s not enough…
FDA questions NurOwn’s efficacy, quality ahead of today’s hearing
The U.S. Food and Drug Administration (FDA) has shared its major concerns with data available for NurOwn,…
New guidelines: All ALS patients should be offered genetic testing
Every person with amyotrophic lateral sclerosis (ALS) should be offered genetic testing to check for the most common…
PathMaker launches first human trial to test noninvasive ALS device
PathMaker Neurosystems has launched a Phase 1 clinical trial that will test its experimental noninvasive nerve-modulating device in…
Ultomiris failed to show benefit in ALS in clinical trial, per full data
Treatment with Ultomiris (ravulizumab-cwvz) — a therapy approved for several rare diseases that works by blocking activation of part…
Bryostatin-1 boosts cell survival in lab model of ALS
Bryostatin-1, a molecule being developed to treat amyotrophic lateral sclerosis (ALS), improved cell survival in a lab model of…
TDP-43 more likely to clump if it can’t form two-protein complexes
When the TDP-43 protein is less able to form two-protein complexes called dimers, it appears to be more likely to form…